Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head Lice

Conditions

Head Lice

Trial Timeline

Jan 1, 2014 → May 1, 2014

About Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + Placebo

Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + Placebo is a phase 1 stage product being developed by Dr. Reddy's Laboratories for Head Lice. The current trial status is completed. This product is registered under clinical trial identifier NCT02061813. Target conditions include Head Lice.

What happened to similar drugs?

11 of 20 similar drugs in Head Lice were approved

Approved (11) Terminated (0) Active (9)

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02061813Phase 1Completed

Competing Products

20 competing products in Head Lice

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40
Docetaxel + Erlotinib + ChemotherapyAstellas PharmaPhase 2
35